Conferences - Results from #8980

ESMO 2017: IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma September 11, 2017

ESMO 2017: Patient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castration-resistant prostate cancer: results from the CABADOC randomized trial September 11, 2017

ESMO 2017: Progression-free survival by independent review and updated overall survival results from Alliance A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma September 11, 2017

ESMO 2017: Adding abiraterone for patients with high-risk prostate cancer (PCa) starting long-term ADT: Outcomes in non-metastatic (M0) patients from STAMPEDE September 11, 2017

ESMO 2017: What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis September 11, 2017

ESMO 2017: Phase Ib/II Trial of Interleukin-2 and Nivolumab in Metastatic Clear Cell Renal Cell Cancer September 11, 2017

ESMO 2017: CheckMate 214: Efficacy and safety of Nivolumab + Ipilimumab vs Sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups September 11, 2017

ESMO 2017: KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma September 11, 2017

ESMO 2017: Will RANGE study impact the standard of care in metastatic urothelial carcinoma? September 11, 2017

ESMO 2017: A Phase III, Randomized, Double-Blind, Multicenter Study of Adjuvant Nivolumab vs Placebo in Patients with High-Risk Invasive Urothelial Carcinoma (CheckMate 274) September 11, 2017

ESMO 2017: Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial September 11, 2017

ESMO 2017: RANGE: A randomized, double-blind, placebo controlled phase 3 study of docetaxel with or without ramucirumab in platinum refractory advanced or metastatic urothelial carcinoma September 11, 2017

ESMO 2017: PRORADIUM: Prospective Multi-Centre Study of Prognostic Factors in Castration Resistant Prostate Cancer Patients Treated with Radium-223 September 10, 2017

ESMO 2017: First Interim Results of the Radium-223 REASSURE Observational Study: Analysis of Patient Characteristics and Safety by Use of Abiraterone and/or Enzalutamide September 10, 2017

ESMO 2017: Outcomes of Prechemotherapy Abiraterone Acetate or Enzalutamide for mCRPC after ADT + Docetaxel or ADT alone for mHSPC September 10, 2017

ESMO 2017: Indirect Comparison of Abiraterone Acetate and Docetaxel for Treatment of Metastatic “Hormone-Sensitive” Prostate Cancer September 10, 2017

ESMO 2017: Pazopanib or Sorafenib + Radium-223 in Metastatic Renal Cell Carcinoma with Bone Metastases September 10, 2017

ESMO 2017: Atezolizumab in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma: Post-Progression Outcomes from the Phase 2 IMvigor210 Study September 10, 2017

ESMO 2017: Epithelial-mesenchymal transition, T cell infiltration, and outcomes with nivolumab in urothelial cancer September 10, 2017

ESMO 2017: Pembrolizumab versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer: mature results from the phase 3 KEYNOTE-045 trial September 10, 2017

Page 450 of 594